Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis

Chest

Volumn 134, Issue 1, 2008, Pages 187-192

  Condos, Rany ^a   Hadgiangelis, Nicos ^b   Leibert, Eric ^a   Jacquette, Germaine ^a   Harkin, Timothy ^c   Rom, William N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Odyssey House   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Extensively drug resistant tuberculosis; Linezolid

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN; CAPREOMYCIN; CIPROFLOXACIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PYRAZINAMIDE; RECOMBINANT GAMMA INTERFERON; RIFABUTIN; STREPTOMYCIN;

ADOLESCENT; ADULT; ARTICLE; BACTERIUM CULTURE; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANCE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCHOOL CHILD; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOSIS; UNITED STATES;

EID: 47549119545     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1988     Document Type: Article

References (24)

1. Goble M, Iseman MD, Madsen LA, et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328:527-532
2. Park MM, Davis AL, Schluger NW, et al. Outcome of MDR-TB patients, 1983-1993: prolonged survival with appropriate therapy. Am J Respir Crit Care Med 1996; 153: 317-324
3. Yew WW, Chan CK, Leung CC, et al. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong. Chest 2003; 124:1476-1481
4. Horsburgh CR Jr. The global problem of multidrug-resistant tuberculosis: the genie is out of the bottle. JAMA 2000; 283:2575-2576
5. Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40:839-845
6. Cynamon MH, Klemens SP, Sharpe CA, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43:1189-1191
7. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB): a report of ten cases. J Infect 2006; 52:92-96
8. Fortun J, Martin-Davila P, Navas E, et al. Linezolid for thetreatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005; 56:180-185
9. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-γ via aerosol. Lancet 1997; 349:1513-1515
10. Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control. Chest 2006; 130:261-272
11. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med 1993; 329:784-790
12. Bozeman L, Burman W, Metchock B, et al. Fluoroquinolone susceptibility among Mycobacterium tuberculosis isolates from the United States and Canada. Clin Infect Dis 2005; 40:386-391
13. Grimaldo ER, Tupasi TE, Rivera AB, et al. Increased resistance to ciprofloxacin and ofloxacin in multidrug-resistant Mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines. Int J Tuberc Lung Dis 2001; 5:546-550
14. Shih PH, Bonk S, Rom WN, et al. Incidence of quinolone resistance in multidrug-resistant tuberculosis [abstract]. Am J Respir Crit Care Med 2003; 167:A869
15. Shinabarger DL, Marotti KR, Murray RW, et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob Agents Chemother 1997; 41:2132-2136
16. Honeybourne D, Tobin C, Jevons G, et al. Intrapulmonary penetration of linezolid. J Antimicrob Chemother 2003; 51:1431-1434
17. Pascual A, Ballesta S, Garcia I, et al. Uptake and intracellular activity of linezolid in human phagocytes and nonphagocytic cells. Antimicrob Agents Chemother 2002; 46: 4013-4015
18. Brown-Elliott BA, Crist CJ, Mann LB, et al. In vitro activity of linezolid against slowly growing nontuberculous Mycobacteria. Antimicrob Agents Chemother 2003; 47: 1736-1738
19. Valencia ME, Moreno V, Laguna F, et al. Multiresistant tuberculosis caused by Mycobacterium bovis and human immunodeficiency virus infection: are there new therapeutic possibilities? Enferm Infecc Microbiol Clin 2001; 19:37-39
20. Rubinstein E, Isturiz R, Standiford HC, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47:1824-1831
21. French G. Safety and tolerability of linezolid. J Antimicrob Chemother 2003; 51(suppl):ii45-ii53
22. Meissner HC, Townsend T, Wenman W, et al. Hematologic effects of linezolid in young children. Pediatr Infect Dis J 2003; 22(suppl):S186-S192
23. Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007; 27:1189-1197
24. Tahaoglu K, Torun T, Sevim T, et al. The treatment of multidrug-resistant tuberculosis in Turkey. N Engl J Med 2001; 345:170-174